MARKETS
Analyst Actions

RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target

Sep 24, 2026 · 09:27 AM ET· updated 23h ago

RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.

Share
Why It Matters

An important analyst says Aardvark stock will match the industry's ups and downs. They think the fair price stays at six dollars per share.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.